KTTA vs BIIB: Which Stock is Better?

Side-by-side comparison of Pasithea Therapeutics Corp and Biogen Inc in 2026

Comparison Updated:

KTTA

Pasithea Therapeutics Corp

$0.74

BIIB

Biogen Inc

$177.35

Key Metrics Comparison

MetricKTTABIIBWinner
Market Cap$18.36M$26.03BBIIB
P/E RatioN/A20.04BIIB
EPS (TTM)$N/A$8.85BIIB
Revenue Growth15.0%-0.1%KTTA
Gross Margin-0.5%78.9%BIIB

Analyze KTTA

Full quant analysis

Analyze BIIB

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is KTTA or BIIB a better investment?

Comparing KTTA and BIIB: Pasithea Therapeutics Corp has a market cap of $18.36M while Biogen Inc has $26.03B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between KTTA and BIIB?

KTTA (Pasithea Therapeutics Corp) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: KTTA or BIIB?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: KTTA or BIIB?

KTTA has higher revenue growth at 15.0% vs -0.1% for BIIB.

Which company is more profitable: KTTA or BIIB?

Biogen Inc (BIIB) has higher gross margins at 78.9% compared to -0.5% for KTTA.

Which is the larger company: KTTA or BIIB?

Biogen Inc (BIIB) is larger with a market cap of $26.03B compared to $18.36M for KTTA.

Should I buy KTTA or BIIB in 2026?

Both KTTA and BIIB have investment merit. KTTA trades at $0.74 while BIIB trades at $177.35. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between KTTA and BIIB stock?

Key differences: Market Cap ($18.36M vs $26.03B), P/E Ratio (N/A vs 20.0x), Revenue Growth (15.0% vs -0.1%), Gross Margin (-0.5% vs 78.9%).

Popular Stock Comparisons